A report of the clinical studies on the use of pyribenzamine in allergic diseases by the Committee on Pharmaceuticals and Medicaments of the American Academy of Allergy.
CHOBOT
R
R
D000047:Academies and Institutes; D000707:Anaphylaxis / Q000628:therapy*; D035843:Biomedical Research; D006967:Hypersensitivity / Q000628:therapy*; D007154:Immune System Diseases; D014309:Tripelennamine; D014481:United States
D014309:Tripelennamine